Physician profile
Juan E Kusnir
NPI 1649546631
$2,839.84
in general payments reported to CMS, 2019-2025
23 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $201 · 2021: $451 · 2022: $318 · 2023: $564 · 2024: $632 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598 · Education: $31.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.77 |
| Education | $31.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $546.23 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $514.05 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $279.17 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $237.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.96 | 2021-2024 | |
| Ardelyx, INC. | $147.94 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $96.63 | 2020 | |
| Mallinckrodt Hospital Products INC. | $94.30 | 2024-2025 | Acthar |
| Amgen INC. | $88.07 | 2019-2025 | Krystexxa |
| Calliditas Therapeutics US INC. | $86.13 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $75.86 | 2022-2025 | |
| Glaxosmithkline, LLC. | $66.87 | 2021-2023 | Jesduvroq |
| Medtronic, INC. | $59.14 | 2023 | Ellipsys Vascular Access System |
| Opko Pharmaceuticals, LLC | $57.75 | 2020-2024 | Rayaldee |
| Horizon Therapeutics Plc | $54.94 | 2023 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.31 | 2025 | |
| Akebia Therapeutics INC | $47.49 | 2024 | Vafseo, Auryxia |
| Novo Nordisk INC | $35.73 | 2025 | Ozempic |
| Mallinckrodt Enterprises LLC | $26.39 | 2019 | |
| Cycle Pharmaceuticals INC | $25.00 | 2024 | Tiopronin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2024 | Jardiance |
| Fresenius USA Marketing, INC. | $18.47 | 2023 | Velphoro |
| Daiichi Sankyo INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Kusnir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.